Clinical Trial Update: MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating MT2021-08T, a T-cell receptor alpha/beta-depleted donor peripheral blood stem cell product, for hematologic malignancies, curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Juvenile Myelomonocytic Leukemia
• Lymphoblastic Lymphoma
• Myelodysplastic Syndromes
• Non-hodgkin Lymphoma

Drugs mentioned

• MT2021-08T (T-cell receptor alpha/beta-depleted donor peripheral blood stem cell product)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Hematologic Malignancy, Acute Leukemia | Phase 2 | Status: RECRUITING